Current European Clinical Trial Plan:
- Expect to conduct an active comparator study with sub-cutaneous apomorphine
- Up to 80 patients will be randomized in a 4-week open label crossover study
- Functional endpoints will be assessed and will include the duration of ON, preference and ease-of-use
of APL-130277, the use of patient diaries, and tolerability of APL-130277 - The use of an anti-emetic should be limited during the study
- Based on current trial timing, the European clinical trial is expected to commence in the fourth quarter of 2016
